To examine whether METTL3 or IGF2BP3 inhibition–mediated suppression of tumor progression was dependent on PD-L1 in vivo, we used MDA-MB-231 cells (stable METTL3-knockdown, IGF2BP3-knockdown, and simultaneous PD-L1 overexpression [rescue condition]) and subcutaneously injected them into female B-NDG mice for tumor xenograft. The gene discussed is METTL3; the disease is neoplasm.